# Advanced Development of Vaccines for Filoviruses

> **NIH NIH N01** · AURO VACCINES LLC · 2021 · $986,612

## Abstract

To support the advanced development of multivalent vaccine candidates for filoviruses and Lassa Fever. This contract aims to formulate a multivalent vaccine that provides protection against several pathogens, including Ebola virus, Marburg virus and Lassa Fever. It may support cGMP manufacture of a stable lyophilized vaccine formulation and preparation and submission of an IND to support eventual clinical evaluation.

## Key facts

- **NIH application ID:** 10382998
- **Project number:** 75N93020C00040-P00001-9999-1
- **Recipient organization:** AURO VACCINES LLC
- **Principal Investigator:** JOHN ELDRIDGE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $986,612
- **Award type:** —
- **Project period:** 2020-07-21 → 2026-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10382998

## Citation

> US National Institutes of Health, RePORTER application 10382998, Advanced Development of Vaccines for Filoviruses (75N93020C00040-P00001-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10382998. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*